{"id":62184,"date":"2025-11-11T13:03:53","date_gmt":"2025-11-11T12:03:53","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/fda-approves-promega-oncomate-msi-dx-analysis-system-as-companion-diagnostic-for-keytruda-in-combination-with-lenvima-in-advanced-endometrial-carcinoma\/"},"modified":"2025-11-11T13:03:53","modified_gmt":"2025-11-11T12:03:53","slug":"fda-approves-promega-oncomate-msi-dx-analysis-system-as-companion-diagnostic-for-keytruda-in-combination-with-lenvima-in-advanced-endometrial-carcinoma","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/fda-approves-promega-oncomate-msi-dx-analysis-system-as-companion-diagnostic-for-keytruda-in-combination-with-lenvima-in-advanced-endometrial-carcinoma\/","title":{"rendered":"FDA Approves Promega OncoMate\u00ae MSI Dx Analysis System as Companion Diagnostic for KEYTRUDA\u00ae in Combination with LENVIMA\u00ae In Advanced Endometrial Carcinoma"},"content":{"rendered":"
\n

\nPromega MSI technology will aid in the identification of patients with microsatellite stable (MSS) endometrial carcinoma<\/i><\/p>\n

MADISON, Wis.–(BUSINESS WIRE)–The U.S. Food and Drug Administration (FDA) has approved the Promega<\/a> OncoMate\u00ae <\/sup>MSI Dx Analysis System as a companion diagnostic designed to identify patients with microsatellite stable (MSS; defined as not MSI-high [not MSI-H]) endometrial carcinoma who may benefit from treatment with KEYTRUDA\u00ae<\/sup> (pembrolizumab), Merck\u2019s anti-PD-1 therapy, plus LENVIMA\u00ae<\/sup> (lenvatinib), the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai. This is the first Promega companion diagnostic to receive FDA approval.<\/p>\n

<\/a>
<\/a><\/p>\n

\nOncoMate\u00ae<\/sup> MSI Dx Analysis System is a PCR-based assay designed to evaluate MSI status in tumor tissue. MSI status can be used to guide treatment decisions and support precision oncology strategies in endometrial carcinoma.<\/p>\n

\n\u201cThis approval underscores the critical role diagnostics play in accurately matching the right patients, at the right time with the right therapy,\u201d says Alok Sharma, Global Clinical Market Director at Promega. \u201cWe are committed to delivering reliable tools that guide clinical decisions and help improve patient outcomes.\u201d<\/p>\n

\nThe approval was supported through a collaboration with Merck, which markets KEYTRUDA plus LENVIMA in collaboration with Eisai Co., Ltd. Together, the companies are working to advance personalized medicine and expand access to diagnostics that enable informed therapeutic choices.<\/p>\n

\nOncoMate\u00ae<\/sup> MSI Dx Analysis System was previously cleared by the FDA as the first PCR-based molecular diagnostic for identifying colorectal cancer patients who may benefit from additional testing to diagnose Lynch syndrome. This approval applies to the United States and its territories. Promega MSI technology has received additional regulatory approvals in China and the European Union.<\/p>\n

\nLearn more about Promega MSI technology here<\/a>.<\/p>\n

\nKEYTRUDA\u00ae<\/sup> is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.<\/p>\n

\nAbout Promega Corporation<\/b><\/p>\n

\nPromega Corporation is a leader in providing innovative solutions and technical support to the life sciences industry. The company\u2019s portfolio of over 4,000 products supports a range of life science work across areas such as cell biology; DNA, RNA and protein analysis; drug development; human identification and molecular diagnostics. These tools and technologies have grown in their application over the last 45 years and are used today by scientists and technicians in labs for academic and government research, forensics, pharmaceuticals, clinical diagnostics and veterinary, agricultural and environmental testing. Promega is headquartered in Madison, WI, USA with branches in 16 countries and over 50 global distributors. Learn more at promega.com<\/a><\/p>\n

Contacts<\/b> <\/p>\n

\nPenny Patterson
\n
VP, Corporate Affairs
\n
Promega Corporation
\n
Phone: (608) 274-4330
\n
E-mail: penny.patterson@promega.com<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Promega MSI technology will aid in the identification of patients with microsatellite stable (MSS) endometrial carcinoma MADISON, Wis.–(BUSINESS WIRE)–The U.S. Food and Drug Administration (FDA) has approved the Promega OncoMate\u00ae MSI Dx Analysis System as a companion diagnostic designed to identify patients with microsatellite stable (MSS; defined as not MSI-high [not MSI-H]) endometrial carcinoma who … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-62184","6":"format-standard","7":"category-industry"},"yoast_head":"\nFDA Approves Promega OncoMate\u00ae MSI Dx Analysis System as Companion Diagnostic for KEYTRUDA\u00ae in Combination with LENVIMA\u00ae In Advanced Endometrial Carcinoma - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/fda-approves-promega-oncomate-msi-dx-analysis-system-as-companion-diagnostic-for-keytruda-in-combination-with-lenvima-in-advanced-endometrial-carcinoma\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FDA Approves Promega OncoMate\u00ae MSI Dx Analysis System as Companion Diagnostic for KEYTRUDA\u00ae in Combination with LENVIMA\u00ae In Advanced Endometrial Carcinoma - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Promega MSI technology will aid in the identification of patients with microsatellite stable (MSS) endometrial carcinoma MADISON, Wis.–(BUSINESS WIRE)–The U.S. Food and Drug Administration (FDA) has approved the Promega OncoMate\u00ae MSI Dx Analysis System as a companion diagnostic designed to identify patients with microsatellite stable (MSS; defined as not MSI-high [not MSI-H]) endometrial carcinoma who ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/fda-approves-promega-oncomate-msi-dx-analysis-system-as-companion-diagnostic-for-keytruda-in-combination-with-lenvima-in-advanced-endometrial-carcinoma\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-11T12:03:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20251110201643\/en\/1865153\/22\/2017_PromegaLogo_Sol_2.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fda-approves-promega-oncomate-msi-dx-analysis-system-as-companion-diagnostic-for-keytruda-in-combination-with-lenvima-in-advanced-endometrial-carcinoma\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fda-approves-promega-oncomate-msi-dx-analysis-system-as-companion-diagnostic-for-keytruda-in-combination-with-lenvima-in-advanced-endometrial-carcinoma\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"FDA Approves Promega OncoMate\u00ae MSI Dx Analysis System as Companion Diagnostic for KEYTRUDA\u00ae in Combination with LENVIMA\u00ae In Advanced Endometrial Carcinoma\",\"datePublished\":\"2025-11-11T12:03:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fda-approves-promega-oncomate-msi-dx-analysis-system-as-companion-diagnostic-for-keytruda-in-combination-with-lenvima-in-advanced-endometrial-carcinoma\\\/\"},\"wordCount\":445,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fda-approves-promega-oncomate-msi-dx-analysis-system-as-companion-diagnostic-for-keytruda-in-combination-with-lenvima-in-advanced-endometrial-carcinoma\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251110201643\\\/en\\\/1865153\\\/22\\\/2017_PromegaLogo_Sol_2.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fda-approves-promega-oncomate-msi-dx-analysis-system-as-companion-diagnostic-for-keytruda-in-combination-with-lenvima-in-advanced-endometrial-carcinoma\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fda-approves-promega-oncomate-msi-dx-analysis-system-as-companion-diagnostic-for-keytruda-in-combination-with-lenvima-in-advanced-endometrial-carcinoma\\\/\",\"name\":\"FDA Approves Promega OncoMate\u00ae MSI Dx Analysis System as Companion Diagnostic for KEYTRUDA\u00ae in Combination with LENVIMA\u00ae In Advanced Endometrial Carcinoma - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fda-approves-promega-oncomate-msi-dx-analysis-system-as-companion-diagnostic-for-keytruda-in-combination-with-lenvima-in-advanced-endometrial-carcinoma\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fda-approves-promega-oncomate-msi-dx-analysis-system-as-companion-diagnostic-for-keytruda-in-combination-with-lenvima-in-advanced-endometrial-carcinoma\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251110201643\\\/en\\\/1865153\\\/22\\\/2017_PromegaLogo_Sol_2.jpg\",\"datePublished\":\"2025-11-11T12:03:53+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fda-approves-promega-oncomate-msi-dx-analysis-system-as-companion-diagnostic-for-keytruda-in-combination-with-lenvima-in-advanced-endometrial-carcinoma\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fda-approves-promega-oncomate-msi-dx-analysis-system-as-companion-diagnostic-for-keytruda-in-combination-with-lenvima-in-advanced-endometrial-carcinoma\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fda-approves-promega-oncomate-msi-dx-analysis-system-as-companion-diagnostic-for-keytruda-in-combination-with-lenvima-in-advanced-endometrial-carcinoma\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251110201643\\\/en\\\/1865153\\\/22\\\/2017_PromegaLogo_Sol_2.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251110201643\\\/en\\\/1865153\\\/22\\\/2017_PromegaLogo_Sol_2.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fda-approves-promega-oncomate-msi-dx-analysis-system-as-companion-diagnostic-for-keytruda-in-combination-with-lenvima-in-advanced-endometrial-carcinoma\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"FDA Approves Promega OncoMate\u00ae MSI Dx Analysis System as Companion Diagnostic for KEYTRUDA\u00ae in Combination with LENVIMA\u00ae In Advanced Endometrial Carcinoma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"FDA Approves Promega OncoMate\u00ae MSI Dx Analysis System as Companion Diagnostic for KEYTRUDA\u00ae in Combination with LENVIMA\u00ae In Advanced Endometrial Carcinoma - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/fda-approves-promega-oncomate-msi-dx-analysis-system-as-companion-diagnostic-for-keytruda-in-combination-with-lenvima-in-advanced-endometrial-carcinoma\/","og_locale":"en_US","og_type":"article","og_title":"FDA Approves Promega OncoMate\u00ae MSI Dx Analysis System as Companion Diagnostic for KEYTRUDA\u00ae in Combination with LENVIMA\u00ae In Advanced Endometrial Carcinoma - Pharma Trend","og_description":"Promega MSI technology will aid in the identification of patients with microsatellite stable (MSS) endometrial carcinoma MADISON, Wis.–(BUSINESS WIRE)–The U.S. Food and Drug Administration (FDA) has approved the Promega OncoMate\u00ae MSI Dx Analysis System as a companion diagnostic designed to identify patients with microsatellite stable (MSS; defined as not MSI-high [not MSI-H]) endometrial carcinoma who ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/fda-approves-promega-oncomate-msi-dx-analysis-system-as-companion-diagnostic-for-keytruda-in-combination-with-lenvima-in-advanced-endometrial-carcinoma\/","og_site_name":"Pharma Trend","article_published_time":"2025-11-11T12:03:53+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20251110201643\/en\/1865153\/22\/2017_PromegaLogo_Sol_2.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/fda-approves-promega-oncomate-msi-dx-analysis-system-as-companion-diagnostic-for-keytruda-in-combination-with-lenvima-in-advanced-endometrial-carcinoma\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/fda-approves-promega-oncomate-msi-dx-analysis-system-as-companion-diagnostic-for-keytruda-in-combination-with-lenvima-in-advanced-endometrial-carcinoma\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"FDA Approves Promega OncoMate\u00ae MSI Dx Analysis System as Companion Diagnostic for KEYTRUDA\u00ae in Combination with LENVIMA\u00ae In Advanced Endometrial Carcinoma","datePublished":"2025-11-11T12:03:53+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/fda-approves-promega-oncomate-msi-dx-analysis-system-as-companion-diagnostic-for-keytruda-in-combination-with-lenvima-in-advanced-endometrial-carcinoma\/"},"wordCount":445,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/fda-approves-promega-oncomate-msi-dx-analysis-system-as-companion-diagnostic-for-keytruda-in-combination-with-lenvima-in-advanced-endometrial-carcinoma\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20251110201643\/en\/1865153\/22\/2017_PromegaLogo_Sol_2.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/fda-approves-promega-oncomate-msi-dx-analysis-system-as-companion-diagnostic-for-keytruda-in-combination-with-lenvima-in-advanced-endometrial-carcinoma\/","url":"https:\/\/pharma-trend.com\/en\/fda-approves-promega-oncomate-msi-dx-analysis-system-as-companion-diagnostic-for-keytruda-in-combination-with-lenvima-in-advanced-endometrial-carcinoma\/","name":"FDA Approves Promega OncoMate\u00ae MSI Dx Analysis System as Companion Diagnostic for KEYTRUDA\u00ae in Combination with LENVIMA\u00ae In Advanced Endometrial Carcinoma - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/fda-approves-promega-oncomate-msi-dx-analysis-system-as-companion-diagnostic-for-keytruda-in-combination-with-lenvima-in-advanced-endometrial-carcinoma\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/fda-approves-promega-oncomate-msi-dx-analysis-system-as-companion-diagnostic-for-keytruda-in-combination-with-lenvima-in-advanced-endometrial-carcinoma\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20251110201643\/en\/1865153\/22\/2017_PromegaLogo_Sol_2.jpg","datePublished":"2025-11-11T12:03:53+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/fda-approves-promega-oncomate-msi-dx-analysis-system-as-companion-diagnostic-for-keytruda-in-combination-with-lenvima-in-advanced-endometrial-carcinoma\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/fda-approves-promega-oncomate-msi-dx-analysis-system-as-companion-diagnostic-for-keytruda-in-combination-with-lenvima-in-advanced-endometrial-carcinoma\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/fda-approves-promega-oncomate-msi-dx-analysis-system-as-companion-diagnostic-for-keytruda-in-combination-with-lenvima-in-advanced-endometrial-carcinoma\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20251110201643\/en\/1865153\/22\/2017_PromegaLogo_Sol_2.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20251110201643\/en\/1865153\/22\/2017_PromegaLogo_Sol_2.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/fda-approves-promega-oncomate-msi-dx-analysis-system-as-companion-diagnostic-for-keytruda-in-combination-with-lenvima-in-advanced-endometrial-carcinoma\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"FDA Approves Promega OncoMate\u00ae MSI Dx Analysis System as Companion Diagnostic for KEYTRUDA\u00ae in Combination with LENVIMA\u00ae In Advanced Endometrial Carcinoma"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62184","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=62184"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62184\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=62184"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=62184"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=62184"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}